TOKYO & BASKING RIDGE, N.J.–(DWPR)–ENHERTU® has been approved in the United States for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen. This approval marks a significant advancement in cancer treatment, offering a targeted therapeutic option for patients who meet specific criteria. Developed collaboratively by Daiichi Sankyo and AstraZeneca, ENHERTU® represents a new hope for individuals battling this challenging condition.

“The approval of ENHERTU® is a critical step forward in addressing unmet needs for patients with HER2-positive metastatic breast cancer. This innovative treatment provides new opportunities to enhance patient outcomes,” said a representative from Daiichi Sankyo.

About ENHERTU®

ENHERTU® is an antibody-drug conjugate specifically designed for targeting HER2. It has been developed through a joint collaboration between Daiichi Sankyo and AstraZeneca, leveraging advanced technology to combat metastatic breast cancer effectively. Visit daiichisankyo.com for more information.

Contacts

Daiichi Sankyo Communications
Jane Doe
[email protected]
(800) 555-1212